溃疡性结肠炎
叙述性评论
叙述的
医学
重症监护医学
内科学
疾病
艺术
文学类
作者
Sneha Annie Sebastian,Oroshay Kaiwan,Edzel Lorraine Co,Meghana Mehendale,Babu P. Mohan
出处
期刊:Spartan medical research journal
[Michigan State University College of Osteopathic Medicine Statewide Campus System]
日期:2024-09-09
卷期号:9 (3)
摘要
Introduction Ulcerative colitis (UC) is a chronic inflammatory bowel disorder (IBD) with periods of relapse and remission. Current advancements in clinical research have led to the development of more refined and effective medical therapy for UC. Summary of the Evidence Traditional therapeutic agents such as 5-aminosalicylates (5-ASAs), sulfasalazine (SASP), corticosteroids, and immunomodulatory drugs have remained the gold standard for decades. However, their novel formulations and dosage regimens have changed their sequences in the medical management of UC. Several other novel drugs are in the final phases of clinical development or have recently received regulatory approval designed to target specific mechanisms involved in the inflammatory cascade for UC. Conclusions This narrative review sought to provide a comprehensive knowledge of the potential benefits of standard and emerging therapies, including novel formulations, new chemical entities, and novel therapeutic approaches in managing UC. Keywords: Ulcerative colitis, 5- Aminosalicylic acid, sulfasalazine, corticosteroids, biologics, immunomodulators, novel formulations
科研通智能强力驱动
Strongly Powered by AbleSci AI